Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting

被引：7

作者：

Maggi, Paolo ^{[1
]}

Ricci, Elena Delfina ^{[2
]}

Martinelli, Canio Vito ^{[3
]}

De Socio, Giuseppe Vittorio ^{[4
]}

Squillace, Nicola ^{[5
]}

Molteni, Chiara ^{[6
]}

Masiello, Addolorata ^{[1
]}

Orofino, Giancarlo ^{[7
]}

Menzaghi, Barbara ^{[8
]}

Bellagamba, Rita ^{[9
]}

Vichi, Francesca ^{[10
]}

Celesia, Benedetto Maurizio ^{[11
]}

Madeddu, Giordano ^{[12
]}

Pellicano, Giovanni Francesco ^{[13
]}

Carleo, Maria Aurora ^{[14
]}

Cascio, Antonio ^{[15
]}

Parisini, Andrea ^{[16
]}

Taramasso, Lucia ^{[17
]}

Valsecchi, Laura ^{[18
]}

Calza, Leonardo ^{[19
]}

Rusconi, Stefano ^{[20
]}

Sarchi, Eleonora ^{[21
]}

Martini, Salvatore ^{[22
]}

Bargiacchi, Olivia ^{[23
]}

Falasca, Katia ^{[24
]}

Cenderello, Giovanni ^{[25
]}

Ferrara, Sergio ^{[26
]}

Di Biagio, Antonio ^{[17
]}

Bonfanti, Paolo ^{[27
]}

机构：

[1] AORN St Anna & San Sebastiano, Infect Dis Unit, I-81100 Caserta, Italy

[2] Fdn ASIA Onlus, I-20090 Buccinasco, Italy

[3] Careggi Hosp, AOU Infect & Trop Dis, I-50134 Florence, Italy

[4] Hosp Santa Maria, Infect Dis Unit, I-06156 Perugia, Italy

[5] Fdn IRCCS San Gerardo Tintori, Infect Dis Unit, I-20900 Monza, Italy

[6] A Manzoni Hosp, Unit Infect Dis, I-23900 Lecce, Italy

[7] ASL Citta Torino, Div Infect & Trop Dis 1, I-10149 Turin, Italy

[8] ASST Valle Olona, Unit Infect Dis, I-21052 Busto Arsizio, Italy

[9] Natl Inst Infect Dis Lazzaro Spallanzani Inst Hos, I-00161 Rome, Italy

[10] Santa Maria Annunziata Hosp, Unit Infect Dis, SOC USLCENTRO Firenze 1, I-50012 Florence, Italy

[11] Garibaldi Hosp, Unit Infect Dis, I-95124 Catania, Italy

[12] Univ Sassari, Dept Med Surg & Pharm, Infect Dis Unit, I-07100 Sassari, Italy

[13] Univ Messina, Dept Human Pathol Adult, Infect Dis Unit, I-98125 Messina, Italy

[14] Cotugno Hosp, AO Colli, Infect Dis & Gender Med Unit, I-80131 Naples, Italy

[15] Univ Palermo, Infect Dis Unit, Dept Hlth Promot Mother & Child Care, Internal Med & Med Specialties, I-90127 Palermo, Italy

[16] Galliera Hosp, Dept Infect Dis, I-16128 Genoa, Italy

[17] Univ Genoa, Clin Infect Dis, IRCCS Policlin San Martino Hosp, I-16132 Genoa, Italy

[18] ASST Fatebenefratelli Sacco, Dept Infect Dis 1, I-20157 Milan, Italy

[19] Univ Bologna, IRCCS Policlin St Orsola, Dept Med Surg Sci, Infect Dis Unit, I-40138 Bologna, Italy

[20] Univ Milan, Osped Civile Legnano, Infect Dis Unit, ASST Ovest Milanese, I-20025 Legnano, Italy

[21] St Antonio & Biagio & Cesare Arrigo Hosp, Infect Dis Unit, I-15121 Alessandria, Italy

[22] Univ Hosp Luigi Vanvitelli, Infect Dis Unit, I-80138 Naples, Italy

[23] Osped Maggiore La Carita, Unit Infect Dis, I-28100 Novara, Italy

[24] GD Annunzio Univ, Chieti Pescara, Dept Med & Sci Aging, Clin Infect Dis, I-66100 Chieti, Italy

[25] Sanremo Hosp, Dept Infect Dis, I-18038 San Remo, Italy

[26] Univ Foggia, Dept Clin & Expt Med, Unit Infect Dis, I-71122 Foggia, Italy

[27] Univ Milano Bicocca, Sch Surg & Med, I-20126 Milan, Italy

来源：

VIRUSES-BASEL | 2023年 / 15卷 / 07期

关键词：

HIV infection; ART-experienced; doravirine; rilpivirine; adverse events; metabolic safety; hepatic safety; SAFETY; TOXICITY; EFFICACY; VIRUS;

D O I：

10.3390/v15071612

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Doravirine (DOR) is a newly approved non-nucleoside reverse transcriptase inhibitor (NNRTI). We aimed to investigate, in a real-life setting, how switching to a DOR-based regimen rather than a rilpivirine (RPV)-based regimen impacted metabolic and hepatic safety. The analysis included 551 antiretroviral treatment (ART)-experienced people living with HIV (PLWH), starting RPV-based or DOR-based regimens with viral load < 200 copies/mL, baseline (T0), and at least one control visit (6-month visit, T1). We enrolled 295 PLWH in the RPV and 256 in the DOR cohort. At T1, total cholesterol (TC), low-density lipoprotein-C (LDL-C), and triglycerides significantly decreased in both DOR and RPV cohorts, while high-density lipoprotein-C (HDL-C) only decreased in RPV-treated people. Consistently, the TC/HDL-C ratio declined more markedly in the DOR (-0.36, p < 0.0001) than in the RPV cohort (-0.08, p = 0.25) (comparison p = 0.39). Similar trends were observed when excluding the PLWH on lipid-lowering treatment from the analysis. People with normal alanine aminotransferase (ALT) levels showed a slight ALT increase in both cohorts, and those with baseline ALT > 40 IU/L experienced a significant decline (-14 IU/L, p = 0.008) only in the DOR cohort. Lipid profile improved in both cohorts, and there was a significant reduction in ALT in PLWH with higher-than-normal baseline levels on DOR-based ART.

引用

页数：12

共 24 条

[21] Hepatotoxicity of Contemporary Antiretroviral Drugs: A Review and Evaluation of Published Clinical Data
Otto, Ashley O.
Rivera, Christina G.
Zeuli, John D.
Temesgen, Zelalem
[J]. CELLS, 2021, 10 (05)
[22] The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial
Santos, Jose R.
Saumoy, Maria
Curran, Adrian
Bravo, Isabel
Llibre, Josep M.
Navarro, Jordi
Estany, Carla
Podzamczer, Daniel
Ribera, Esteban
Negredo, Eugenia
Clotet, Bonaventura
Paredes, Roger
[J]. CLINICAL INFECTIOUS DISEASES, 2015, 61 (03) : 403 - 408
[23] Neuropsychiatric Effects of HIV Antiviral Medications
Treisman, Glenn J.
Soudry, Olivia
[J]. DRUG SAFETY, 2016, 39 (10) : 945 - 957
[24] Weight and Metabolic Outcomes in Naive HIV Patients Treated with Integrase Inhibitor-Based Antiretroviral Therapy: A Systematic Review and Meta-Analysis
Valenzuela-Rodriguez, German
Diaz-Arocutipa, Carlos
Collins, Jaime A. A.
Hernandez, Adrian V. V.
[J]. JOURNAL OF CLINICAL MEDICINE, 2023, 12 (11)

← 1 2 3 →